Industry experts Michelangelo Canzoneri, Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 guide core team –...
Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5...
Japanese drugmaker Takeda plans to invest about $765 million to build a new manufacturing facility in Osaka for plasma-derived therapies (PDTs). The company said the sum...
Japanese pharma Takeda is acquiring Nimbus Lakshmi, a wholly-owned subsidiary of US clinical-stage drug discovery company Nimbus Therapeutics, and its tyrosine kinase 2...
The International Society for Pharmaceutical Engineering (ISPE) has announced Takeda Pharmaceuticals International as the 2022 Facility of the Year Awards (FOYA) Overall...
Following a multi-year collaboration, Japanese pharma Takeda has exercised its option to buy the UK’s GammaDelta Therapeutics for a pre-negotiated upfront sum, as well as...
Japanese drugmaker Takeda has clarified its plans to produce and distribute the Novavax Covid-19 shot in the country, if and when it is approved. After several delays, in...
Industry experts Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 group – talk about the idea behind ISPE’s Pharma...
